Purpose, strategy and culture

Vaccines

Vaccines help protect people from infectious diseases at every stage of life. Our vaccines portfolio is the broadest in the industry, helping protect people from meningitis, shingles, flu, polio, measles and many more. Today, two million doses of our vaccines are administered daily, and 4 in 10 of the world’s children receive a GSK jab each year. We use diverse platform technologies from adjuvants that improve vaccine effectiveness through to mRNA technology. These are at the heart of our pipeline differentiation.

Specialty medicines

Specialty medicines are prescribed by specialist healthcare practitioners. For GSK this includes our cancer medicines that have life-changing potential for patients. We’re also developing medicines for immune-mediated conditions, including the first new medicine for the chronic autoimmune condition lupus in 50 years.

We are global leaders in developing medicines for HIV. Having pioneered the first HIV treatments in the 1980s, our goal now is to limit the impact of HIV on people’s lives by treating, preventing and ultimately curing it.

General medicines

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. For us, this includes our inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Every day, these medicines improve health and make life better for millions of people all over the world. For more than 50 years, we’ve helped millions of people with respiratory conditions to breathe more easily, including the first inhalers in 1969, and we remain the industry leader in respiratory science.

Infectious diseases image

Almost half the vaccines and medicines in our pipeline address infectious diseases, helping protect people from diseases like meningitis, shingles, flu, polio, measles and many more.

HIV

Our long-acting HIV medicines have the potential to dramatically change people’s experience by giving them an alternate to daily medicine.

Oncology

We develop cancer medicines with life-changing potential for patients with ovarian cancer, endometrial cancer and multiple myeloma. We’ve accelerated this research and currently have three marketed therapies and a further nine assets in development.

Immunology

Our focus on the science of the immune system helps us develop vaccines and medicines for a range of immune-mediated conditions, including the first new medicine for the chronic autoimmune condition lupus in 50 years.

Opportunity-driven therapies

We also pursue other opportunity-driven therapies where the science aligns with our strategic approach. This includes the work we are doing to help the one in seven of the 700 million chronic kidney disease sufferers with anaemia.